Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
Vera Therapeutics Inc. Class A Common Stock
VERA | US
42.30
USD0.06
0.14%
VERA | US
About Vera Therapeutics Inc. Class A Common Stock
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
17/04/2026
Close
42.30
Open
42.75
High
44.07
Low
42.05
Vera Therapeutics Inc. a clinical stage biotechnology company focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept a fusion protein self-administered as a subcutaneous injection that is in Phase IIb clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis. It is also developing MAU868 a monoclonal antibody for the treatment of BK viremia infections. The company was formerly known as Trucode Gene Repair Inc. and changed its name to Vera Therapeutics Inc. in April 2020. Vera Therapeutics Inc. was incorporated in 2016 and is headquartered in Brisbane California.
View LessVERA | US
Risk
55.3
Sharpe
0.98
Luna's Score
49/100
Recommendation
Hold
Luna says (VERA | US)
What's Working
Low Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
What's not Working
High Short-term Volatility
Midcap (2B - 10B USD)
High Market Beta (> 0.8)
High Short percentage (> 15%)
Volatility Signals
Bearish: Increased Volatility (6-month > 1-month volatility)
Risk Meter
10 days
59.7%1 month
55.3%3 months
48.2%6 months
64.8%Returns
Fundamental Ratios
PE
-
Fwd. PE
-
Price to book
6.88
Debt to equity
0.16
Debt to assets
0.13
Ent. to EBITDA
-3.60
Ent. to rev.
-
PEG
-
Other Fundamentals
EBITDA
-90.73M
MarketCap
2.32B
MarketCap(USD)
2.32B
Div. yield
-
Op. margin
-
Erngs. growth
-
Rev. growth
-
Ret. on equity
-46.05
Short ratio
9.65
Short perc.
15.83
Market Sentiment (SMA and Price signals)
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
SMAs: Stock Price Trends
Range10D
7.90
Range1M
9.49
Range3M
11.82
Volumes: Market Activity
Rel. volume
0.85
Price X volume
48.57M
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -3.60 | - | Cheaper |
| Ent. to Revenue | - | - | - |
| PE Ratio | - | 41.03 | - |
| Price to Book | 6.88 | 15.55 | Cheaper |
| Dividend Yield | - | - | - |
| Std. Deviation (3M) | 48.17 | - | Lower Risk |
| Debt to Equity | 0.16 | -1.23 | Expensive |
| Debt to Assets | 0.13 | 0.25 | Cheaper |
| Market Cap | 2.32B | - | Emerging |
